GSE66207

mRNA and small RNA associated with Crohn's disease behavior [RNA-Seq]

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

20 case / 13 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

There is a need for reliable prognostic markers that can guide therapeutic intervention in Crohn’s disease (CD). We examined whether different behavioral phenotypes in CD can be classified based on colonic miRNA or mRNA expression and if miRNAs have prognostic utility for CD. We perform high-throughput sequencing of small RNA and mRNA isolated from colon tissue from CD patients and non-IBD (NIBD) controls. To identify miRNA and genes associated with specific behavioral phenotypes of CD, patients were stratified according to disease behavior (non-stricturing, non-penetrating; stricturing; penetrating) and compared miRNA profiles in each class with those of the NIBD group. Using a novel statistical simulation approach applied to colonic RNA-seq data for CD patients and NIBD controls, we identify at drivers of gene expression profiles associated with CD.

Overall design

Macroscopically non-inflamed colon tissue from well-characterized Crohn's disease patients and normal controls were obtained. Small RNA-seq and RNA-seq were performed on these samples. Additionally, we investigated the effect of inflammation on miRNA expression by performing small RNA-seq on matched colon samples obtained from macroscopically inflamed regions from a subset (six) of these patients with Crohn's Disease.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
33 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Curated expression experiment linkage and source URL.

Expression Atlas accession
E-GEOD-66207
Available
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

3 linked publications 3 DOIs

Primary publication

  1. MicroRNAs Classify Different Disease Behavior Phenotypes of Crohn's Disease and May Have Prognostic Utility. Inflammatory bowel diseases, 2015

Related publications

  1. Identification and multimodal characterization of a specialized epithelial cell type associated with Crohn's disease. Nature communications, 2024
  2. An alternative splicing signature in human Crohn's disease. BMC gastroenterology, 2021
Available

Metadata Quality Components

Analysis Readiness

Review before analysis
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • Secondary RNA assay context should be analyzed separately from ordinary bulk RNA-seq.

Next Steps

  • Review blockers and update sample grouping or dataset selection before analysis.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Disease context Crohn's disease, colorectal cancer, inflammatory bowel disease Disease context came from Normalization rules.
  • Likely case group Inflamed tissue 20 samples
  • Likely control group Mixed controls 13 samples

Ranking Facts

Supporting evidence

  • Comparison: Disease/model vs control. Specimen: Biopsy. Comparison suitability: 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Interpreted disease metadata: Colorectal cancer, Crohn's disease, Inflammatory bowel disease.
  • Processed data is available for downstream review.
  • External evidence: Expression Atlas curated experiment link is available.
  • External evidence: PubMed links 3 publications; 3 DOIs available: PMID 26164662, PMID 34749666, PMID 39169060.
  • Publication context: MicroRNAs Classify Different Disease Behavior Phenotypes of Crohn's Disease and May Have Prognostic Utility.. Inflammatory bowel diseases, 2015. PMID 26164662. DOI 10.1097/MIB.0000000000000478.
  • Publication context: An alternative splicing signature in human Crohn's disease.. BMC gastroenterology, 2021. PMID 34749666. DOI 10.1186/s12876-021-02001-2.
  • Publication context: Identification and multimodal characterization of a specialized epithelial cell type associated with Crohn's disease.. Nature communications, 2024. PMID 39169060. DOI 10.1038/s41467-024-51580-7.

Cautions

  • Disease/control design without a tumor/normal comparison is outside tumor/normal triage.
  • Small RNA, miRNA, circRNA, or extracellular-vesicle RNA context downgraded for primary mRNA tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because secondary RNA assays are not primary mRNA tissue RNA-seq.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

150 fields

Sample Group Preview

33 rows shown
Show Hide
Study totals: Case 20 | Control 13 | Unassigned 0 | Excluded 0 | Ambiguous 0 33 rows shown
Group Role Accession Title Source / characteristics Reason
Inflamed tissue Case GSM1616912 B2/stricturing Crohn's disease [RNA-Seq, 20_CD_NI_B2] Colon Age: 15; Sex: Male; Disease: Crohn's Disease; Disease_stage: B2/stricturing; Inflamed: No; Montreal classification: A1L1B2 Case marker detected.
Inflamed tissue Case GSM1616913 B2/stricturing Crohn's disease [RNA-Seq, 21_CD_NI_B2] Colon Age: 51; Sex: Female; Disease: Crohn's Disease; Disease_stage: B2/stricturing; Inflamed: No; Montreal classification: A2L2B2 Case marker detected.
Inflamed tissue Case GSM1616914 B3/penetrating Crohn's disease [RNA-Seq, 29_CD_NI_B3] Colon Age: 59; Sex: Female; Disease: Crohn's Disease; Disease_stage: B3/penetrating; Inflamed: No; Montreal classification: A2L3B3 Case marker detected.
Inflamed tissue Case GSM1616915 B2/stricturing Crohn's disease [RNA-Seq, 51_CD_NI_B2] Colon Age: 30; Sex: Female; Disease: Crohn's Disease; Disease_stage: B2/stricturing; Inflamed: No; Montreal classification: A2L3B2 Case marker detected.
Inflamed tissue Case GSM1616916 B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 54_CD_NI_B1] Colon Age: 20; Sex: Male; Disease: Crohn's Disease; Disease_stage: B1/non-strictuing, non-penetrating; Inflamed: No; Montreal classification: A1L2B1 Case marker detected.
Inflamed tissue Case GSM1616917 B3/penetrating Crohn's disease [RNA-Seq, 62_CD_NI_B3] Colon Age: 45; Sex: Female; Disease: Crohn's Disease; Disease_stage: B3/penetrating; Inflamed: No; Montreal classification: A2L3B3 Case marker detected.
Inflamed tissue Case GSM1616918 B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 63_CD_NI_B1] Colon Age: 49; Sex: Male; Disease: Crohn's Disease; Disease_stage: B1/non-strictuing, non-penetrating; Inflamed: No; Montreal classification: A1L3B1 Case marker detected.
Inflamed tissue Case GSM1616919 B3/penetrating Crohn's disease [RNA-Seq, 64_CD_NI_B3] Colon Age: 49; Sex: Female; Disease: Crohn's Disease; Disease_stage: B3/penetrating; Inflamed: No; Montreal classification: A2L3B3 Case marker detected.
Inflamed tissue Case GSM1616920 B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 405_CD_NI_B1] Colon Age: 56; Sex: Female; Disease: Crohn's Disease; Disease_stage: B1/non-strictuing, non-penetrating; Inflamed: No; Montreal classification: A2L2B1 Case marker detected.
Inflamed tissue Case GSM1616921 B3/penetrating Crohn's disease [RNA-Seq, 407_CD_NI_B3] Colon Age: 43; Sex: Female; Disease: Crohn's Disease; Disease_stage: B3/penetrating; Inflamed: No; Montreal classification: A2L2B3p Case marker detected.
Inflamed tissue Case GSM1616922 B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 408_CD_NI_B1] Colon Age: 23; Sex: Female; Disease: Crohn's Disease; Disease_stage: B1/non-strictuing, non-penetrating; Inflamed: No; Montreal classification: A2L2B1 Case marker detected.
Inflamed tissue Case GSM1616923 B3/penetrating Crohn's disease [RNA-Seq, 413_CD_NI_B1] Colon Age: 32; Sex: Female; Disease: Crohn's Disease; Disease_stage: B3/penetrating; Inflamed: No; Montreal classification: A2L2B1 Case marker detected.
Inflamed tissue Case GSM1616924 B2/stricturing Crohn's disease [RNA-Seq, 420_CD_NI_B2] Colon Age: 37; Sex: Female; Disease: Crohn's Disease; Disease_stage: B2/stricturing; Inflamed: No; Montreal classification: A2L2B2p Case marker detected.
Inflamed tissue Case GSM1616925 B2/stricturing Crohn's disease [RNA-Seq, 422_CD_NI_B2] Colon Age: 21; Sex: Female; Disease: Crohn's Disease; Disease_stage: B2/stricturing; Inflamed: No; Montreal classification: A1L3B2 Case marker detected.
Inflamed tissue Case GSM1616926 B3/penetrating Crohn's disease [RNA-Seq, 424_CD_NI_B3] Colon Age: 34; Sex: Male; Disease: Crohn's Disease; Disease_stage: B3/penetrating; Inflamed: No; Montreal classification: A2L3B3 Case marker detected.
Inflamed tissue Case GSM1616927 B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 429_CD_NI_B1] Colon Age: 25; Sex: Female; Disease: Crohn's Disease; Disease_stage: B1/non-strictuing, non-penetrating; Inflamed: No; Montreal classification: A2L3B1 Case marker detected.
Inflamed tissue Case GSM1616928 B1/non-strituring, non-penetrating Crohn's disease [RNA-Seq, 431_CD_NI_B1] Colon Age: 20; Sex: Female; Disease: Crohn's Disease; Disease_stage: B1/non-strictuing, non-penetrating; Inflamed: No; Montreal classification: A1L2B1 Case marker detected.
Inflamed tissue Case GSM1616929 B3/penetrating Crohn's disease [RNA-Seq, 434_CD_NI_B3] Colon Age: 31; Sex: Male; Disease: Crohn's Disease; Disease_stage: B3/penetrating; Inflamed: No; Montreal classification: A2L3B3 Case marker detected.
Inflamed tissue Case GSM1616930 B2/stricturing Crohn's disease [RNA-Seq, 440_CD_NI_B2] Colon Age: 76; Sex: Male; Disease: Crohn's Disease; Disease_stage: B2/stricturing; Inflamed: No; Montreal classification: A2L3B2 Case marker detected.
Inflamed tissue Case GSM1616931 B3/penetrating Crohn's disease [RNA-Seq, 450_CD_NI_B3] Colon Age: 28; Sex: Female; Disease: Crohn's Disease; Disease_stage: B3/penetrating; Inflamed: No; Montreal classification: A2L1B3 Case marker detected.
Normal tissue Control GSM1616932 Normal colon biopsy, female age 53 [RNA-Seq, 22_NIBD_NI] Colon Age: 53; Sex: Female; Disease: Normal; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Normal tissue Control GSM1616933 Normal colon acquired during Hartmann reversal after colon cancer, male age 52 [RNA-Seq, 23_NIBD_NI] Colon Age: 52; Sex: Male; Disease: Normal, Hartmann reversal after colon cancer; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Normal tissue Control GSM1616934 Normal colon biopsy acquired during surgery for diverticulitis,female age 60 [RNA-Seq, 25_NIBD_NI] Colon Age: 60; Sex: Female; Disease: Normal, diverticulitis; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Normal tissue Control GSM1616935 Normal colon acquired during surgery for diverticulitis, male age 70 [RNA-Seq, 27_NIBD_NI] Colon Age: 70; Sex: Male; Disease: Normal, diverticulitis; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Normal tissue Control GSM1616936 Normal colon biopsy acquired during surgery for colon cancer, female age 82 [RNA-Seq, 30_NIBD_NI] Colon Age: 82; Sex: Female; Disease: Normal, Colon cancer; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Normal tissue Control GSM1616937 Normal colon acquired during surgery for colon cancer, male age 44 [RNA-Seq, 32_NIBD_NI] Colon Age: 44; Sex: Male; Disease: Normal, Colon cancer; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Normal tissue Control GSM1616938 Normal colon acquired during surgery for colonic inertia, female age 41 [RNA-Seq, 36_NIBD_NI] Colon Age: 41; Sex: Female; Disease: Normal, colonic inertia, TI submucosal hemorrhage (but looked inflamed on macro); Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Normal tissue Control GSM1616939 Normal colon acquired during surgery for colon cancer, male age 52 [RNA-Seq, 39_NIBD_NI] Colon Age: 52; Sex: Male; Disease: Normal, Colon cancer; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Healthy control Control GSM1616940 Normal colon acquired during surgery for large polyp, male age 65 [RNA-Seq, 42_NIBD_NI] Colon Age: 65; Sex: Male; Disease: Normal control, large polyp; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Normal tissue Control GSM1616941 Normal colon acquired during surgery for colonic inertia, female age 45 [RNA-Seq, 43_NIBD_NI] Colon Age: 45; Sex: Female; Disease: Normal, colonic inertia; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Normal tissue Control GSM1616942 Normal colon acquired during surgery for adenoma, male age 70 [RNA-Seq, 48_NIBD_NI] Colon Age: 70; Sex: Male; Disease: Normal, Adenoma; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Normal tissue Control GSM1616943 Normal colon acquired during surgery for adenoma, male age 62 [RNA-Seq, 49_NIBD_NI] Colon Age: 62; Sex: Male; Disease: Normal, Adenoma; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.
Normal tissue Control GSM1616944 Normal colon acquired during surgery for small intestine neuroendocrine tumor, female age 49 [RNA-Seq, 50_NIBD_NI] Colon Age: 49; Sex: Female; Disease: Normal, SI Neuroendocrine tumor; Disease_stage: NA; Inflamed: No; Montreal classification: NA Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.